COLLABORATE El Meu Clínic . This link opens in a new tab.
Search
COLLABORATE El Meu Clínic . This link opens in a new tab.
Navigation thread
Clínic Barcelona
Research

IDIBAPS celebrates the kick-off meeting of the Metabolism and Disease Program (MetaDis)

This program aims to decipher the mechanisms underlying metabolic diseases through molecular and systemic studies, analyse interactions between organs and perform patient-focused trials. It also seeks to determine the impact of factors such as nutrition, exercise, microbiota and ageing to provide a global understanding of these diseases.

On Monday, March 10, the launch of the “Metabolism and Disease Program (MetaDis): a multidisciplinary approach to deciphering metabolic diseases” was held in the Esteve auditorium of the CEK. The event was attended by all the heads or representatives of the research groups, as well as numerous members of the laboratories that are part of them:

Metabolic diseases, such as obesity, diabetes and cardiovascular, hepatic, endocrine diseases, or cancer pose one of the main challenges to public health and have serious socioeconomic implications. These diseases involve many different organs and systems, which makes a multidisciplinary approach essential to understand their pathogenesis in a comprehensive and global way. MetaDis was created to address these challenges from a holistic perspective to promote more effective prevention and management.

The new research program has three objectives:

  • Deciphering pathogenic mechanisms. This includes understanding the mechanisms responsible for metabolic diseases, identifying key interactions between the organs involved and discovering new biomarkers and therapeutic targets.
  • Study of determinant factors. MetaDis will analyse how diet, exercise, microbiota and ageing influence the progression of metabolic diseases. The programme will also investigate the role of the circadian rhythm in modulating ageing and in the development of age-related diseases.
  • Develop innovative methodologies and new therapeutic approaches. MetaDis will create patient-derived models and murine models that accurately replicate human metabolic diseases. It also aims to make progress in personalised treatments and explore drug repurposing for potential new indications.

This comprehensive approach will allow MetaDis to make headway in our understanding and treatment of metabolic diseases, offering innovative and effective solutions for a problem with great social impact.

About IDIBAPS research programmes

In 2022, IDIBAPS launched a new initiative to promote collaboration between its research groups called ‘Multidisciplinary research programmes’. The programmes bring together various IDIBAPS groups to facilitate collaboration, especially between basic and clinical groups. Both junior and senior researchers are involved in these programmes and female leadership is promoted.

There are currently five programmes under way:

Keep reading about:

Related news